Mylan is proud to be one of the largest pharmaceutical employers in Ireland, with a broad and growing portfolio of biosimilar, generic, brand and over-the-counter medicines that includes antiretrovirals.
Leaders in the treatment of allergy, women's health, pancreatic exocrine insufficiency, HIV and anaphylaxis, you can learn more about our portfolio by accessing a list of approved medicines here.
Our customers include consumers, retail and pharmacy establishments, wholesalers, governments, institutions and healthcare professionals.
Ensuring Quality and Safety are Our Highest Priorities
We know that what we do directly impacts the health and well-being of patients. As a result, protecting patients and consumer health by ensuring the quality and safety of our products is at the heart of how we operate across our network. From product development to making or sourcing raw materials to producing finished dosage forms, every step of our development, manufacturing and monitoring processes is grounded in this commitment.
We employ a team of highly-trained scientists and technical professionals with extensive experience in the pharmaceutical industry to develop each product formulation and to identify the specific processes and technologies used to manufacture our products. All our applications are subject to a robust regulatory review before a product can be brought to market. We monitor the performance of our products after approval and identify and implement any changes necessary to ensure quality. Significant changes also are subject to review by regulatory agencies.
Reporting Side Effects:
If you experience any side effects, please talk to your doctor or pharmacist. This includes any possible side effects not listed in the patient information leaflet.
You can also report side effects directly via the Health Products Regulatory Authority (HPRA) website: http://www.hpra.ie/homepage/medicines/safety-information/reporting-suspected-side-effects
You should also report any side effects to Mylan Ireland Pharmacovigilance on +44 (0)800 121 8267 or e-mail: UKPharmacovigilance@mylan.com.
DOP: August 2019